Biological barriers to cellular delivery of lipid-based DNA carriers
Section snippets
Foreword
The challenge that one faces when writing a review is to identify a focus. This is a difficult task in the area of gene therapy because the technologies and therapeutic applications are so diverse. A brief search of the MEDLINE data base of scientific literature indicated that over 300 reviews on gene therapy were published over a 9 month period ending in September 1997, the time when this review was prepared. A cursory examination of these reviews leaves one with the feeling that researchers
Introduction to the technology
Recent advances in molecular genetics have contributed significantly to our understanding of disease pathogenesis [1], [2]. A logical extension of this new understanding concerns the development of therapeutic strategies that specifically target genetic abnormalities [3], [4]. Advances in molecular biology have resulted in a new concept for treatment of disease, the concept of gene therapy. Gene therapy can be defined as any treatment strategy that relies on the introduction of polynucleotides
Defining the ‘activities’ of lipid-based plasmid delivery systems
In order to develop useful plasmid delivery systems, the carrier formulation must fulfill many ‘activities’ in order to facilitate transgene expression. If the activity of the delivery system is defined in a narrow context, then one can judiciously address how individual components of the delivery systems affect specific requirements, such as protection of the associated DNA. Although six steps have been defined in Fig. 1 as requirements for a therapeutically useful gene transfer system, in the
Preparation of lipid–DNA complexes
The concept of using lipid-based carriers for delivery of DNA to cells resulted from an extensive amount of research on the use of liposomes as drug carriers [40]. As DNA carriers, this technology relied on capturing DNA within the aqueous compartments of multilamellar liposomes during their formation; a simple process requiring hydration of dried lipids with a solution containing DNA. The liposomes were typically prepared using neutral and/or anionic lipids and under ideal conditions these
The first barrier: protection of the plasmid expression vector
The physical characteristics of the lipoplexes being developed for delivery of plasmid expression vectors must protect the associated DNA from factors that will prevent transgene expression. Superficially, lipid-mediated protection of plasmid expression vectors is easy to measure, easy to achieve and most approaches used to prepare lipoplexes result in some level of DNA protection, as assessed by inhibition of DNA intercalating dye binding and DNA stability in the presence of DNase I or serum
The second barrier: binding to the cell membrane
In general, lipoplex formulations that give rise to optimal transfection in vitro and in vivo are prepared such that the structure generated exhibits a net positive charge [63], [64]. It has been argued that the positive charge facilitates binding to cell membranes, which have an anionic surface. We believe that this argument is too simplistic. As suggested above, lipoplex formulations tend to aggregate in the presence of salts and this aggregation reaction can be attributed to the surface
The third barrier: DNA delivery and dissociation from the carrier
Once a lipoplex interacts with a cell membrane, DNA enters the cell either directly through the plasma membrane or indirectly following endocytosis. Both entry routes require membrane destabilization and, regardless of whether the destabilized membrane is the plasma membrane or the endosomal membrane, these and/or other intracellular processes must also involve dissociation of the plasmid expression vector from the lipoplex. A pivotal manuscript addressing potential mechanism(s) of
The fourth barrier: transfer into the nucleus
Cationic lipid-mediated transfection is a relatively inefficient process, which is initiated by binding of the plasmid expression vector to the cell [64], [98]. While a significant portion of the cell-associated DNA is internalized, only a small percentage of DNA is released from endosomes. Therefore, only a small amount of DNA will be available as free DNA in the cytoplasm, and this DNA will still be susceptible to degradation. This free DNA must still find its way to the nucleus. An unlikely
Summary – lipoplex design challenges
Our interest in developing lipid-based carriers with attributes that change as a function of time following i.v. administration has been summarized here. Other investigators are focusing on developing model (reconstituted) viruses as efficient nucleic acid delivery systems. The three viral attributes that have attracted the greatest attention are (i) surface binding interactions [125], (ii) viral membrane fusion proteins [126] and (iii) nuclear targeting signals [127]. Based on what is known
Acknowledgements
The Medical Research Council of Canada and Inex Pharmaceuticals Corp. supports research on gene transfer formulations in M. Bally’s laboratory. D. Reimer was a MRC Postdoctoral Fellow. E. Wasan holds a fellowship from the British Columbia Science Council. F. Wong is a recipient of a Cancer Research Society Studentship.
References (128)
- et al.
The scope of gene therapy in humans: scientific, safety and ethical considerations
Neuromuscular Disord.
(1997) - et al.
Comparison of various expression plasmids for the induction of immune response by DNA immunization
Mol. Cells
(1997) Harnessing viral devices as pharmaceuticals: fighting HIV-1’s fire with fire
Cell
(1997)Molecular diagnostics for cystic fibrosis
Clin. Lab. Med.
(1997)Naked DNA transport and expression in mammalian cells
Neuromuscular Disord.
(1997)- et al.
Integration of foreign DNA and its consequences in mammalian systems
Trends Biotechnol.
(1997) - et al.
Alteration of the DNA secondary structure in the DNA–polylysine complex evidenced by sodium bisulfite modification
FEBS Lett.
(1979) DNA condensation
Curr. Opin. Struct. Biol.
(1996)- et al.
Binding of cationic alpha-helical peptides to plasmid DNA and their gene transfer abilities into cells
J. Biol. Chem.
(1997) - et al.
Encapsulation of high molecular weight DNA in large unilamellar phospholipid vesicles. Dependence on the size of the DNA
FEBS Lett.
(1979)
Physicochemical and pharmacokinetic characteristics of plasmid DNA/cationic liposome complexes
J. Pharm. Sci.
Plasmid DNA is protected against ultrasonic cavitation-induced damage when complexed to cationic liposomes
J. Pharm. Sci.
Lipid/DNA complexes as an intermediate in the preparation of particles for gene transfer: an alternative to cationic liposome/DNA aggregates
Adv. Drug Deliv. Rev.
Biophysical characterization of cationic lipid:DNA complexes
Biochim. Biophys. Acta
New structures in complex formation between DNA and cationic liposomes visualized by freeze-fracture electron microscopy
FEBS Lett.
Characterization of lipid DNA interactions I: Destabilization of bound lipids and DNA dissociation
Biophys. J.
Analysis of cationic liposome-mediated interactions of plasmid DNA with murine and human melanoma cells in vitro
J. Biol. Chem.
Contribution of trypsin-sensitive proteins to binding of cationic liposomes to the mouse macrophage-like cell line RAW264.7
J. Pharm. Sci.
Efficient gene transfer with less cytotoxicity by means of cationic multilamellar liposomes
Biochem. Biophys. Res. Commun.
Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations
J. Biol. Chem.
Tissue distribution of liposomes exhibiting long half-lives in the circulation after intravenous injection
Biochim. Biophys. Acta
The role of surface charge and hydrophilic groups on liposome clearance in vivo
Biochim. Biophys. Acta
Sterically stabilized liposomes
Biochim. Biophys. Acta
Repulsive interactions and mechanical stability of polymer-grafted lipid membranes
Biochim. Biophys. Acta
Poly(ethylene glycol)–lipid conjugates inhibit phospholipase C-induced lipid hydrolysis, liposome aggregation and fusion through independent mechanisms
FEBS Lett.
Polyethylene glycol modified phospholipids stabilize emulsions prepared from triacylglycerol
J. Pharm. Sci.
Versatility in lipid compositions showing prolonged circulation with sterically stabilized liposomes
Biochim. Biophys. Acta
Liposomes with detachable polymer coating: destabilization and fusion of dioleoylphosphatidylethanolamine vesicles triggered by cleavage of surface-grafted poly(ethylene glycol)
FEBS Lett.
Stabilization of cationic liposome–plasmid DNA complexes by polyamines and poly(ethylene glycol)–phospholipid conjugates for efficient in vivo gene delivery
FEBS Lett.
Biochemical and functional characterization of DNA complexes capable of targeting genes to hepatocytes via the asialoglycoprotein receptor
J. Biol. Chem.
Glycerol and polylysine synergize in their ability to rupture vesicular membranes: a mechanism for increased transferrin–polylysine-mediated gene transfer
Exp. Cell Res.
Folate-targeted, anionic liposome-entrapped polylysine-condensed DNA for tumor cell-specific gene transfer
J. Biol. Chem.
Of molecular interactions, mice and mechanisms: new insights into Huntington’s disease
Curr. Opin. Neurol.
Molecular genetics of childhood cancer: implications for pathogenesis, diagnosis, and treatment
Pediatrics
Human gene therapy
Science
Natural antisense RNA/target RNA interactions: possible models for antisense oligonucleotide drug design
Nat. Biotechnol.
Triplex DNA: fundamentals, advances, and potential applications for gene therapy
J. Mol. Med.
Ribozymes. Their functions and strategies for their use
Mol. Biotechnol.
Progress toward the structure and therapeutic use of the hairpin ribozyme
Antisense Nucleic Acid Drug Dev.
Noninfectious gene transfer and expression systems for cancer gene therapy
Semin. Oncol.
Long-term expression of a foreign gene from a unique position in the latent herpes simplex virus genome
Hum. Gene Ther.
Retroviral stem cell gene therapy
Stem Cells
Basics of cancer gene therapy
Anticancer Res.
Gene therapy for lung inflammatory diseases: not so far away?
Thorax
Vascular gene therapy in the 21st century
Thromb. Haemost.
Gene therapy for central nervous system injury: the use of cationic liposomes: an invited review
J. Neurotrauma
Somatic gene therapy for phenylketonuria and other hepatic deficiencies
J. Inherit. Metab. Dis.
Antisense oligonucleotides as therapeutics for malignant diseases
Semin. Oncol.
Antisense therapy
Curr. Opin. Oncol.
Adenoviral/retroviral vector chimeras: a novel strategy to achieve high-efficiency stable transduction in vivo
FASEB J.
Cited by (168)
Evolution of drug delivery systems: From 1950 to 2020 and beyond
2022, Journal of Controlled ReleaseAxial pharmaceutical properties of liposome in cancer therapy: Recent advances and perspectives
2020, International Journal of PharmaceuticsMineral-Coated Microparticles Enhance mRNA-Based Transfection of Human Bone Marrow Cells
2019, Molecular Therapy Nucleic AcidsNovel machine learning application for prediction of membrane insertion potential of cell-penetrating peptides
2019, International Journal of PharmaceuticsRecent advances in applying nanotechnologies for cancer immunotherapy
2018, Journal of Controlled ReleaseNanoparticles for DNA delivery
2017, Advances in Nanomedicine for the Delivery of Therapeutic Nucleic Acids